Older prostate cancer patients with three or more underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by UCLA urologists.

The FDA has approved radium Ra 223 dichloride (Xofigo) injection for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.

A new study has confirmed that a genetic test that measures cell cycle progression (CCP) can be a useful tool for predicting which patients will have prostate cancer recurrence, especially when combined with existing information from laboratory and pathology tests.

Initial success rates of abdominal sacrocolpopexy for pelvic organ prolapse decline over the long term, according to a recently published multicenter study.

Pediatric urology surgeon David Roth, MD, has been named the chief of urology at Texas Children’s Hospital in Houston.